These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 34146514)

  • 1. Progress towards therapies for disease modification in Parkinson's disease.
    Vijiaratnam N; Simuni T; Bandmann O; Morris HR; Foltynie T
    Lancet Neurol; 2021 Jul; 20(7):559-572. PubMed ID: 34146514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing in Parkinson's Disease.
    Athauda D; Foltynie T
    CNS Drugs; 2018 Aug; 32(8):747-761. PubMed ID: 30066310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease in the Era of Personalised Medicine: One Size Does Not Fit All.
    Ryden LE; Lewis SJG
    Drugs Aging; 2019 Feb; 36(2):103-113. PubMed ID: 30556112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic targets for Parkinson's disease.
    Stoessl J
    Expert Opin Ther Targets; 2008 Apr; 12(4):425-36. PubMed ID: 18348679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease.
    Bloem BR; Marks WJ; Silva de Lima AL; Kuijf ML; van Laar T; Jacobs BPF; Verbeek MM; Helmich RC; van de Warrenburg BP; Evers LJW; intHout J; van de Zande T; Snyder TM; Kapur R; Meinders MJ
    BMC Neurol; 2019 Jul; 19(1):160. PubMed ID: 31315608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease modifying therapies III: Novel targets.
    Vijiaratnam N; Foltynie T
    Neuropharmacology; 2021 Dec; 201():108839. PubMed ID: 34656651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parkinson's disease. Second of two parts.
    Lang AE; Lozano AM
    N Engl J Med; 1998 Oct; 339(16):1130-43. PubMed ID: 9770561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in Parkinson's disease: Advances and strategies.
    Delenclos M; Jones DR; McLean PJ; Uitti RJ
    Parkinsonism Relat Disord; 2016 Jan; 22 Suppl 1(Suppl 1):S106-10. PubMed ID: 26439946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease?
    Lenka A; Jankovic J
    Expert Rev Neurother; 2023 Feb; 23(2):107-122. PubMed ID: 36803618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges in the diagnosis of Parkinson's disease.
    Tolosa E; Garrido A; Scholz SW; Poewe W
    Lancet Neurol; 2021 May; 20(5):385-397. PubMed ID: 33894193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dilemma between milestones of progression versus clinical scales in Parkinson's disease.
    Greenland JC; Camacho M; Williams-Gray CH
    Handb Clin Neurol; 2023; 192():169-185. PubMed ID: 36796941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Personalized treatment of Parkinson's disease].
    Brockmann K; Gasser T
    Nervenarzt; 2019 Aug; 90(8):767-772. PubMed ID: 31243506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Parkinson's disease : what's on the horizon?
    Wu SS; Frucht SJ
    CNS Drugs; 2005; 19(9):723-43. PubMed ID: 16142989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progress in the molecular pathogenesis and nucleic acid therapeutics for Parkinson's disease in the precision medicine era.
    Li D; Mastaglia FL; Fletcher S; Wilton SD
    Med Res Rev; 2020 Nov; 40(6):2650-2681. PubMed ID: 32767426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Marras C; Fereshtehnejad SM; Berg D; Bohnen NI; Dujardin K; Erro R; Espay AJ; Halliday G; Van Hilten JJ; Hu MT; Jeon B; Klein C; Leentjens AFG; Mollenhauer B; Postuma RB; Rodríguez-Violante M; Simuni T; Weintraub D; Lawton M; Mestre TA
    Mov Disord; 2024 Mar; 39(3):462-471. PubMed ID: 38243775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.
    Foltynie T; Gandhi S; Gonzalez-Robles C; Zeissler ML; Mills G; Barker R; Carpenter J; Schrag A; Schapira A; Bandmann O; Mullin S; Duffen J; McFarthing K; Chataway J; Parmar M; Carroll C;
    Brain; 2023 Jul; 146(7):2717-2722. PubMed ID: 36856727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of modifying disease progression in prediagnostic Parkinson's disease.
    Salat D; Noyce AJ; Schrag A; Tolosa E
    Lancet Neurol; 2016 May; 15(6):637-48. PubMed ID: 26993435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection in Parkinson's disease: myth or reality?
    Voss T; Ravina B
    Curr Neurol Neurosci Rep; 2008 Jul; 8(4):304-9. PubMed ID: 18590614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.